|
Updates to the Management of Cervical Cancer |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Hereditary Cancer Syndromes: MSK CATCH Program (Comprehensive Assessment, Treatment, and Prevention of Cancers with Hereditary Dispositions) |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Remembrance and Renewal: A Holistic Self-Care Program for Oncology Clinicians |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Financial Toxicity of Cancer Care |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Venous Thromboembolism Management in Malignancy |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma? |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Review of Oral Targeted Therapies in Acute Myeloid Leukemia |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Management of CNS Metastases in Patients with Breast Cancer |
0.75 |
03/15/2025 - 12:00am to 03/15/2026 - 12:00am |
|
Updates in Melanoma: A Focus on Neoadjuvant Approaches |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
CRS and ICANS Management in CAR T/Bispecific Antibody Therapies |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
The Spectrum of End-of-Life Care |
0.75 |
06/30/2025 - 12:00am to 03/01/2026 - 12:00am |
|
NCCN Guidelines® Insights - Survivorship, Version 2.2025 |
1.00 |
06/10/2025 - 12:00am to 06/10/2026 - 12:00am |
|
Innovative Strategies to Improve Patient Access |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
Facebook
X
LinkedIn
Forward